BLUE News and Press, bluebird bio Inc. From 06/28/21

ipopba/iStock via Getty Images Several gene editing stocks are flying high in afternoon trading, the beneficiaries of news from over the weekend on Intellia Therapeutics' (NTLA) gene editing candidate NTLA-2001. Besides Intellia, which is currently up 50% in afternoon trading, Beam ...

Pioneering biotech bluebird bio (NASDAQ: BLUE) has resumed clinical trials for its blood disorder gene therapies after getting clearance from the U.S. Food and Drug Administration (FDA). The stock is up more than 10% over the past five days in response, and the FDA's move bodes well...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE). In May 2020, the Company announced its plans t...

bluebird bio (BLUE) presents data from several studies of betibeglogene autotemcel (beti-cel) gene therapy in adult, adolescent and pediatric patients with transfusion-dependent β-thalassemia ((TDT)). A total of 63 patients have been treated with beti-cel in Phase 1/2 HGB-204...

With 51 patients enrolled, data from the long-term follow-up study (LTF-303) show that all patients treated with beti-cel who achieve transfusion independence (TI) remain free from transfusions, with the longest follow-up of seven years Across Phase 3 studies, 89% (32/36) of...

The Food and Drug Administration (FDA) has told bluebird bio (NASDAQ: BLUE) it can resume trials of its experimental gene therapy, LentiGlobin, after it determined the therapy wasn't responsible for a rare case of cancer diagnosed in a trial participant earlier this year. IM...

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42 nd Annual Global Healthcare Conference, Tuesday, June 8, at 8:50 a.m. ET. To access the live webcast of bluebird bio’s presentation, please visit...

bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patie...

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 50,000 shares of common stock and 25,000 restricted stock units (“RSUs”) to its C...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...